1. What unmet needs and challenges do you face when treating patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder? (0:10)
2. Can you give us a brief overview of the mode of action of cytotoxic T lymphocyte (CTL) therapy? (2:03)
3. How will these findings be translated into clinical practice? When are EU and US filings expected, and what will this mean for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder? (3:36)
4. What are the next steps in this area of research? What future opportunities are there in the development of CTLs and other cellular therapies? (4:37)
Speaker disclosures: Mohamad Mohty has nothing to disclose in relation to this interview.
Filmed at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, San Diego, CA, US, 1–4 December 2018.